文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌中度大分割前列腺床照射与全盆腔放疗比较:一项回顾性真实世界单中心队列研究

Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-08-21

该回顾性单中心队列研究纳入2008至2021年在厄勒布鲁大学医院接受中度大分割前列腺床照射(PORT)或全盆腔放疗(WPRT)的516例高危局限期前列腺癌患者,比较肿瘤结局、毒性及生活质量。5年生化失败无生存率PORT为77%、WPRT为74%(校正HR=1.50,95%CI=0.88-2.55),MFS、PCSS、OS无显著差异;WPRT急性≥2级和3级泌尿生殖毒性风险更高,晚期毒性与生活质量无差异。

要点

  • 5年生化失败无生存率PORT 77% vs WPRT 74%,校正HR=1.50(95%CI=0.88-2.55)。
  • MFS、PCSS、OS主要分析均无显著差异。
  • WPRT急性≥2级和3级泌尿生殖毒性风险更高,晚期毒性与生活质量无差异。

核心结论

  • 中度大分割PORT与WPRT在肿瘤结局和生活质量上无显著差异,但毒性模式存在差异。
  • 作者认为,尽管研究设计存在局限,研究结果支持需要进一步研究WPRT对治疗相关和患者报告结局的影响。

研究设计与样本

  • 回顾性真实世界单中心队列研究,纳入2008至2021年厄勒布鲁大学医院516例高危、常规分期(cT1-3N0M0)前列腺癌患者。
  • 患者接受中度大分割WPRT(289例)或PORT(227例),放疗为单纯外照射或联合高剂量率近距离治疗。
  • 采用Kaplan-Meier法和Cox比例风险模型比较BFFS、MFS、PCSS和OS,并分析毒性和生活质量。

主要发现

  • 5年BFFS率PORT为77%、WPRT为74%,校正HR=1.50(95%CI=0.88-2.55)。
  • 主要分析中MFS、PCSS、OS均无显著差异。
  • WPRT与急性≥2级和3级泌尿生殖毒性风险更高相关。
  • PORT与WPRT在晚期毒性和生活质量方面无差异。

局限性

  • 原文述及研究设计存在局限(caveats related to study design)。
  • 作者在结论中提出需要进一步研究WPRT对治疗相关和患者报告结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit of prophylactic whole pelvis radiation therapy (WPRT) in prostate cancer has been debated for decades, with evidence based mainly on conventional fractionation targeting pelvic nodes. AIM: This retrospective cohort study aimed to explore the impact of adding moderately hypofractionated pelvic radiotherapy to prostate-only irradiation (PORT) on prognosis, toxicity, and quality of life in real-world settings. MATERIALS AND METHODS: Patients with high-risk and conventionally staged prostate cancer (cT1-3N0M0) treated with moderately hypofractionated WPRT or PORT, using external beam radiotherapy alone or combined with high-dose-rate brachytherapy, at Örebro University Hospital between 2008 and 2021 were identified. Biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were compared using Kaplan-Meier method and Cox proportional hazards. Toxicity and quality of life measures were also analysed. RESULTS: Among 516 patients (227 PORT, 289 WPRT), 5-year BFFS rates were 77 % (PORT) and 74 % (WPRT), adjusted HR=1.50 (95 % CI=0.88-2.55). No significant differences were found in MFS, PCSS, or OS in main analyses. WPRT was associated with a higher risk of acute grade ≥ 2 and 3 genitourinary toxicities whereas no differences in late toxicities or quality of life between PORT and WPRT were observed. CONCLUSION: We found no significant differences in oncological outcomes or quality of life when comparing moderately hypofractionated PORT to WPRT. Some differences in toxicity patterns were observed. Despite caveats related to study design, our findings support the need for further research on WPRT's impact on treatment-related and patient-reported outcomes.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kahlmeter Brandell J, Valachis A, Ugge H, et al. Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study. Clin Transl Radiat Oncol. 2024. PMID: 39258243. doi:10.1016/j.ctro.2024.100846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。